Medical weight management
Medical Weight Management
Physician-led treatment of overweight or obesity, integrated with joint health, mobility, and pain care when weight is a factor.
- Framework
- Long-term chronic-disease care
- Medication
- One tool, not the entire plan
- Broader outcomes
- Health, function, strength, and sustainable maintenance
Weight care built around health and function.
This is not a generic weight-loss or GLP-1 clinic. For patients living with osteoarthritis, joint pain, limited mobility, or pain that makes activity difficult, medical weight management can be part of a broader plan for health and function. We consider how weight, strength, mobility, medicines, pain treatment, and long-term maintenance fit together without treating weight loss as pain treatment.
The evaluation looks beyond BMI.
BMI is a practical screening measure, but it does not directly measure body composition, fat distribution, fitness, muscle, or an individual’s full health risk. Decisions should also consider weight history, blood pressure, metabolic health, sleep apnea, joint load, function, medicines, prior attempts, access, and goals.
Pain can make weight management harder.
When walking hurts, exercise and rehabilitation can become harder, activity and conditioning may decline, and strength can decline. Some medicines used in pain care may also affect weight or edema. These factors can make a weight-management plan harder to carry out, but they do not make weight the cause of every pain problem.
Weight can sometimes make function harder.
Higher body weight can increase mechanical loading of weight-bearing joints and may make mobility, exercise, or rehabilitation participation harder. These relationships vary by person and do not replace diagnosis or treatment of the pain source.
We track weight, but we also care about what you can do.
When applicable, follow-up may include walking or stair tolerance, exercise or physical-therapy participation, strength or function measures used in care, metabolic health, weight trajectory, and sustainable maintenance. Weight loss can include lean tissue as well as fat, so nutrition and resistance activity may matter. None of these outcomes is guaranteed.
Weight management can be part of knee osteoarthritis care.
For people with knee osteoarthritis and overweight or obesity, supported weight loss, especially alongside exercise, can modestly improve pain and physical function. Weight management is not required to receive knee care and does not replace evaluation of the knee or other appropriate treatments.
Hip osteoarthritis has a smaller direct evidence base.
Guidelines support weight management for people with hip osteoarthritis and overweight or obesity, although direct trial evidence is more limited than for knee osteoarthritis. The hip diagnosis, function, exercise plan, and other treatment choices still need their own evaluation.
Low-back pain remains a separate clinical question.
Higher body weight is associated with back pain in population studies, but clinical trials have not established weight loss as a reliable treatment for chronic low-back pain. If weight management is appropriate for a patient’s overall health, the back-pain diagnosis and treatment plan remain separate.
Prescription medication can be evidence-based care.
FDA-approved long-term options include medicines with different mechanisms, benefits, contraindications, and side effects. GLP-1 receptor agonists and dual GIP/GLP-1 medicines can produce clinically meaningful weight loss for many eligible patients when combined with a broader plan, but response and tolerability vary. A category discussion does not mean a specific product is available or appropriate.
Approved, off-label, and compounded are different.
An FDA-approved product has been reviewed for a specific indication, manufacturing standard, and label. Off-label prescribing uses an approved drug outside its label based on clinical judgment. A compounded drug is not FDA approved and is not reviewed before marketing for safety, effectiveness, or quality. FDA advises that compounded GLP-1 products should be used only when a patient’s medical need cannot be met by an approved drug.
Who may be a candidate?
Medication is commonly considered for adults with BMI at or above 30, or at or above 27 with a weight-related health problem, while recognizing BMI’s limitations. The decision also considers pregnancy plans, gastrointestinal and endocrine history, eating-disorder risk, current medicines, contraindications specific to the drug, cost, access, and long-term preferences.
Your first visit builds the long-term plan.
Care begins with weight trajectory, prior approaches, current medicines, related conditions, nutrition, activity, sleep, function, and personal goals. Baseline testing is individualized. Follow-up evaluates adverse effects, nutrition and strength, functional change, health markers, medication decisions, and whether the plan remains worthwhile.
- Set health and function goals in addition to weight goals
- Review contraindications and medication interactions
- Use an approved prescription only when appropriate
- Track nutrition, symptoms, strength, and relevant health measures
- Plan for maintenance before the active weight-loss phase ends
Weight management and pain treatment should not live in separate charts.
Weight care should account for medicines and procedures used elsewhere in a patient’s care. Gabapentin and pregabalin labeling includes weight gain and peripheral edema among possible adverse effects; a medication review identifies context without assuming a medicine should be stopped. Current multi-society guidance uses patient-specific risk and team decision-making for GLP-1 medicines before anesthesia or deep sedation rather than a blanket hold rule. In people with diabetes, a joint corticosteroid injection can temporarily raise blood glucose, so monitoring and coordination may be appropriate.
Risks and limitations are medicine-specific.
Gastrointestinal symptoms are common with GLP-1-based medicines, and serious events can occur. Rapid loss, inadequate protein or resistance activity, and illness can worsen loss of lean tissue. Cost, coverage, supply, and the possibility of long-term treatment belong in informed consent.
Maintenance and regain deserve honest planning.
Obesity physiology persists after weight loss. Some regain is common after medication is stopped, and long-term treatment may be appropriate when benefit continues and risk remains acceptable. Maintenance can require ongoing medication, nutrition and activity support, and a plan for changing circumstances, not blame.
Alternatives and referrals remain part of care.
A different approved medicine, an intensive lifestyle program, treatment of sleep apnea or another contributing condition, dietitian support, behavioral-health care, physical therapy, or metabolic or bariatric surgery may be more appropriate. The best plan can combine or sequence these options.
When other care is more appropriate
Pregnancy, suspected eating disorder, severe or persistent abdominal symptoms, endocrine red flags, acute illness, or a complex history may require obstetric, gastroenterology, endocrinology, behavioral-health, emergency, or obesity-medicine evaluation before or instead of medication.
Track outcomes that matter to the individual.
We may track outcomes that matter to the person, such as walking or stair tolerance, exercise participation, physical-therapy participation when applicable, strength or function measures actually used in care, relevant metabolic markers, and weight trajectory. These goals can be coordinated with diagnosis-first pain care without promising that weight change will eliminate pain.
Weight management is not a gate to pain care.
A person does not have to lose weight before receiving an evaluation or appropriate pain care at Solutions in Pain. Weight management may be discussed when it fits the person’s health goals, but it does not replace knee, hip, spine, or other diagnosis-specific care.
Questions worth asking
Useful context before a consultation.
General education cannot determine candidacy or replace an individualized medical evaluation.
Are GLP-1 medicines only for people with diabetes?
No. Some GLP-1-based products are FDA approved for chronic weight management in eligible people without diabetes; other products are approved for diabetes. The exact product and indication matter.
What does GLP-1 microdosing mean?
Microdosing is a marketing term rather than one standardized, FDA-approved weight-management regimen. Dose selection must follow the exact medicine, approved labeling when applicable, clinical reason, tolerability, and prescriber judgment; a lower dose should not be advertised as universally safer or more effective.
Is retatrutide offered for weight management?
Retatrutide remains investigational and is not an FDA-approved weight-management medicine. It may be discussed as an area of research, but this page does not present it as an available treatment.
Will I lose muscle?
Weight loss commonly includes some lean mass as well as fat mass. Adequate nutrition, sufficient protein when appropriate, resistance training, a sensible rate of loss, and monitoring help support muscle and function.
What happens if I stop medication?
Some regain is common because the biology that promotes weight regain remains active. Before starting, it is useful to discuss duration, maintenance options, cost, and what would prompt a change.
Is compounded semaglutide or tirzepatide the same as an approved product?
No. Compounded versions are not FDA approved or reviewed before marketing for safety, effectiveness, or quality. Their use requires a patient-specific reason, a lawful source, precise prescribing and dispensing, and a candid discussion of added uncertainty.
